A breakthrough new therapy has enabled mice to survive exposure to acute radiation, according to a new study that may lead to ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Italy Organoids and Spheroids Market Research Report The Italy organoids and spheroids market is projected to reach $36.6 million by 2032, ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, ...

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell products for cancer and autoimmune ... the data continue to ...

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Cells are constantly on the move, whether in a developing embryo or metastatic cancer. But how do cells adapt to the new ...

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

Using the microscopic structures found on the wings of the Morpho butterfly, researchers have developed a simple and inexpensive way to analyze cancer biopsy samples that could make cancer diagnosis ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...